[{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"Astressin B","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sentia Medical Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sentia Medical Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Sentia Medical Science","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"Sentia Medical Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sentia Medical Science \/ Neurocrine Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Sentia Medical Science \/ Neurocrine Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by Sentia Medical Science

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Collaboration leverages Sentia’s platform and Neurocrine’s expertise to develop novel CRF receptor antagonists.

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          April 16, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Discovery

                          Sponsor : Neurocrine Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Under the research collaboration, Sentia’s proprietary peptide-based platform will be used to discover novel compounds as corticotropin-releasing factor receptor antagonist for the treatment of hypothalamic-pituitary-adrenal axis modulated diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          February 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Discovery

                          Sponsor : Neurocrine Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The collaboration will utilize Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal (HPA)...

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          April 27, 2021

                          Lead Product(s) : Astressin B

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Neurocrine Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank